|
1
|
Filipowicz W, Bhattacharyya SN and
Sonenberg N: Mechanisms of post-transcriptional regulation by
microRNAs: Are the answers in sight? Nat Rev Genet. 9:102–114.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Calin GA, Sevignani C, Dumitru CD, Hyslop
T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M,
et al: Human microRNA genes are frequently located at fragile sites
and genomic regions involved in cancers. Proc Natl Acad Sci USA.
101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shi XB, Xue L, Yang J, Ma AH, Zhao J, Xu
M, Tepper CG, Evans CP, Kung HJ and deVere White RW: An
androgen-regulated miRNA suppresses Bak1 expression and induces
androgen-independent growth of prostate cancer cells. Proc Natl
Acad Sci USA. 104:19983–19988. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lu Z, Liu M, Stribinskis V, Klinge CM,
Ramos KS, Colburn NH and Li Y: MicroRNA-21 promotes cell
transformation by targeting the programmed cell death 4 gene.
Oncogene. 27:4373–4379. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sun R, Fu X, Li Y, Xie Y and Mao Y: Global
gene expression analysis reveals reduced abundance of putative
microRNA targets in human prostate tumours. BMC Genomics.
10:932009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pang Y, Young CY and Yuan H: MicroRNAs and
prostate cancer. Acta Biochim Biophys Sin. 42:363–369. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hermeking H: p53 enters the microRNA
world. Cancer Cell. 12:414–418. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lodygin D, Tarasov V, Epanchintsev A,
Berking C, Knyazeva T, Körner H, Knyazev P, Diebold J and Hermeking
H: Inactivation of miR-34a by aberrant CpG methylation in multiple
types of cancer. Cell Cycle. 7:2591–2600. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fujita Y, Kojima K, Hamada N, Ohhashi R,
Akao Y, Nozawa Y, Deguchi T and Ito M: Effects of miR-34a on cell
growth and chemoresistance in prostate cancer PC3 cells. Biochem
Biophys Res Commun. 377:114–119. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mizushima N: Autophagy: Process and
function. Genes Dev. 21:2861–2873. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Choi AM, Ryter SW and Levine B: Autophagy
in human health and disease. N Engl J Med. 368:651–662. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
White E: Deconvoluting the
context-dependent role for autophagy in cancer. Nat Rev Cancer.
12:401–410. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang ZJ, Chee CE, Huang S and Sinicrope
FA: The role of autophagy in cancer: Therapeutic implications. Mol
Cancer Ther. 10:1533–1541. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Korkmaz G, le Sage C, Tekirdag KA, Agami R
and Gozuacik D: miR-376b controls starvation and mTOR
inhibition-related autophagy by targeting ATG4C and BECN1.
Autophagy. 8:165–176. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Frankel LB, Wen J, Lees M, Høyer-Hansen M,
Farkas T, Krogh A, Jäättelä M and Lund AH: microRNA-101 is a potent
inhibitor of autophagy. EMBO J. 30:4628–4641. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Comincini S, Allavena G, Palumbo S, Morini
M, Durando F, Angeletti F, Pirtoli L and Miracco C: microRNA-17
regulates the expression of ATG7 and modulates the autophagy
process, improving the sensitivity to temozolomide and low-dose
ionizing radiation treatments in human glioblastoma cells. Cancer
Biol Ther. 14:574–586. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang J, Chen D, He Y, Meléndez A, Feng Z,
Hong Q, Bai X, Li Q, Cai G, Wang J, et al: MiR-34 modulates
Caenorhabditis elegans lifespan via repressing the autophagy gene
atg9. Age. 35:11–22. 2013. View Article : Google Scholar :
|
|
21
|
Watahiki A and Wang Y, Morris J, Dennis K,
O'Dwyer HM, Gleave M, Gout PW and Wang Y: MicroRNAs associated with
metastatic prostate cancer. PLoS One. 6:e249502011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bommer GT, Gerin I, Feng Y, Kaczorowski
AJ, Kuick R, Love RE, Zhai Y, Giordano TJ, Qin ZS, Moore BB, et al:
p53-mediated activation of miRNA34 candidate tumor-suppressor
genes. Curr Biol. 17:1298–1307. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Welch C, Chen Y and Stallings RL:
MicroRNA-34a functions as a potential tumor suppressor by inducing
apoptosis in neuroblastoma cells. Oncogene. 26:5017–5022. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Di Martino MT, Leone E, Amodio N, Foresta
U, Lionetti M, Pitari MR, Cantafio ME, Gullà A, Conforti F, Morelli
E, et al: Synthetic miR-34a mimics as a novel therapeutic agent for
multiple myeloma: In vitro and in vivo evidence. Clin Cancer Res.
18:6260–6270. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nalls D, Tang SN, Rodova M, Srivastava RK
and Shankar S: Targeting epigenetic regulation of miR-34a for
treatment of pancreatic cancer by inhibition of pancreatic cancer
stem cells. PLoS One. 6:e240992011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li L, Xie X, Luo J, Liu M, Xi S, Guo J,
Kong Y, Wu M, Gao J, Xie Z, et al: Targeted expression of miR-34a
using the T-VISA system suppresses breast cancer cell growth and
invasion. Mol Ther. 20:2326–2334. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Trang P, Wiggins JF, Daige CL, Cho C,
Omotola M, Brown D, Weidhaas JB, Bader AG and Slack FJ: Systemic
delivery of tumor suppressor microRNA mimics using a neutral lipid
emulsion inhibits lung tumors in mice. Mol Ther. 19:1116–1122.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rothe K, Lin H, Lin KB, Leung A, Wang HM,
Malekesmaeili M, Brinkman RR, Forrest DL, Gorski SM and Jiang X:
The core autophagy protein ATG4B is a potential biomarker and
therapeutic target in CML stem/progenitor cells. Blood.
123:3622–3634. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fan X, Wang J, Hou J, Lin C, Bensoussan A,
Chang D, Liu J and Wang B: Berberine alleviates ox-LDL induced
inflammatory factors by up-regulation of autophagy via AMPK/mTOR
signaling pathway. J Transl Med. 13:922015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Herrero-Martín G, Høyer-Hansen M,
García-García C, Fumarola C, Farkas T, López-Rivas A and Jäättelä
M: TAK1 activates AMPK-dependent cytoprotective autophagy in
TRAIL-treated epithelial cells. EMBO J. 28:677–685. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Matsui Y, Takagi H, Qu X, Abdellatif M,
Sakoda H, Asano T, Levine B and Sadoshima J: Distinct roles of
autophagy in the heart during ischemia and reperfusion: Roles of
AMP-activated protein kinase and Beclin 1 in mediating autophagy.
Circ Res. 100:914–922. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sudarsanam S and Johnson DE: Functional
consequences of mTOR inhibition. Curr Opin Drug Discov Devel.
13:31–40. 2010.PubMed/NCBI
|
|
33
|
Jung CH, Ro SH, Cao J, Otto NM and Kim DH:
mTOR regulation of autophagy. FEBS Lett. 584:1287–1295. 2010.
View Article : Google Scholar : PubMed/NCBI
|
